The Indian Patent Office revoked Novartis' patent for Vymada, a heart failure drug, citing a lack of novelty and inventive step. This decis...

In FY23, 30 companies undertook voluntary product recalls, while 16 were forced to recall their products, shows data sourced from Prime Dat...

The scheme can also invest in equities of listed overseas companies, in line with the RBI and SEBI guidelines.

Kumar advised investors to stick to their investment plans.

"There is only one trigger on the downward move of a war threat between the US and North Korea."

"The main patent applications covering sofosbuvir are still pending before the Indian Patent Office," Alton said.

Full Life probably has the staff with the youngest average age among all the companies that Jhunjunwala has invested in.

New Delhi is well within its rights to rebuff the US pharma lobby's attempt to label India a habitual intellectual property rights (IPR) of...

If Novartis had won the case, it would have been granted a monopoly on Glivec, and denied Indian companies the right to make the drug.

Novartis' Glivec is priced at Rs 1.2 lakh whereas local generic versions, which feed most of the poor countries of the world, cost a fourth...

Israeli drugmaker Teva Pharma has filed a patent infringement suit in the US against Lupin that prevents the Indian pharma company from sel...

More than one-fifth of patent examiners have quit during last two years.

The Supreme Court on Tuesday reserved its judgement on pharma major GlaxoSmithKline Plc's petition seeking grant of exclusive marketing rig...

Domestic pharma major Cipla is opposing US-based biotech major Gilead Sciences’ patent application in India for anti-AIDS drug Viread.

In a relief to Hyderabad-based pharma company Hetero Drugs, the Supreme Court on Friday gave it the green signal to manufacture 1% Nadiflox...

While the government is close to striking a deal with the Left on the passage of the Patents Bill, it has found support from an unlikely qu...

There will be no more exclusive marketing right grants in a hurry. The Controller General of Patents and Trademarks has decided to wait for...